Megann A. Boone

Megann A. Boone

Auto-generated profile, based on publicly available information

Megann A. Boone

Biomedical Sciences Graduate Program, The Ohio State University, Columbus, OH, 43210, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 June 2021 in Oncogene
Verified
Journal Article
Open access
PDF file
MBMegann A. Boone
Megann A. Boone
CTCenny Taslim
Cenny Taslim
JCJesse C. Crow
Jesse C. Crow
JSJulia Selich-Anderson
Julia Selich-Anderson
ABAndrea K. Byrum
Andrea K. Byrum
SLStephen L. Lessnick
Stephen L. Lessnick
Ewing sarcoma is an aggressive bone cancer of children and young adults defined by the presence of a chromosomal translocation: t(11;22)(q24;q12). The encoded protein, EWS/FLI, fuses the amino-terminal domain of EWS to the carboxyl-terminus of FLI. The EWS portion is an intrinsically disordered transcriptional regulatory domain, while the FLI portion contains an ETS DNA-binding domain and two flanking regions of unknown function. Early studies using non-Ewing sarcoma models provided conflicting information on the roles of each domain of FLI in EWS/FLI oncogenic function. We therefore sought to define the specific contributions of each FLI domain to EWS/FLI activity in a well-validated Ewing sarcoma model and, in doing so, to better understand Ewing sarcoma development mediated by the fusion protein. We analyzed a series of engineered EWS/FLI mutants with alterations in the FLI portion using a variety of assays. Fluorescence anisotropy, CUT&RUN, and ATAC-sequencing experiments revealed that the isolated ETS domain is sufficient to maintain the normal DNA-binding and chromatin accessibility function of EWS/FLI. In contrast, RNA-sequencing and soft agar colony formation assays revealed that the ETS domain alone was insufficient for transcriptional regulatory and oncogenic transformation functions of the fusion protein. We found that an additional alpha-helix immediately downstream of the ETS domain is required for full transcriptional regulation and EWS/FLI-mediated oncogenesis. These data demonstrate a previously unknown role for FLI in transcriptional regulation that is distinct from its DNA-binding activity. This activity is critical for the cancer-causing function of EWS/FLI and may lead to novel therapeutic approaches.

31 August 2021 in Molecular Cancer Research
Verified
Journal Article
Open access
PDF file
MBMegann A. Boone
Megann A. Boone
CTCenny Taslim
Cenny Taslim
JCJesse C. Crow
Jesse C. Crow
JSJulia Selich-Anderson
Julia Selich-Anderson
MWMike Watson
Mike Watson
MWMark Winstanley
Mark Winstanley
Ewing sarcoma is a pediatric bone cancer defined by a chromosomal translocation fusing one of the FET family members to an ETS transcription factor. There have been seven reported chromosomal translocations, with the most recent reported over a decade ago. We now report a novel FET/ETS translocation involving FUS and ETV4 detected in a patient with Ewing sarcoma. Here, we characterized FUS/ETV4 by performing genomic localization and transcriptional regulatory studies on numerous FET/ETS fusions in a Ewing sarcoma cellular model. Through this comparative analysis, we demonstrate significant similarities across these fusions, and in doing so, validate FUS/ETV4 as a bona fide Ewing sarcoma translocation. This study presents the first genomic comparison of Ewing sarcoma–associated translocations and reveals that the FET/ETS fusions share highly similar, but not identical, genomic localization and transcriptional regulation patterns. These data strengthen the notion that FET/ETS fusions are key drivers of, and thus pathognomonic for, Ewing sarcoma. Implications: Identification and initial characterization of the novel Ewing sarcoma fusion, FUS/ETV4, expands the family of Ewing fusions and extends the diagnostic possibilities for this aggressive tumor of adolescents and young adults.

30 October 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
MBMegann A. Boone
Megann A. Boone
CTCenny Taslim
Cenny Taslim
JCJesse C. Crow
Jesse C. Crow
JSJulia Selich-Anderson
Julia Selich-Anderson
ISIftekhar A. Showpnil
Iftekhar A. Showpnil
SLStephen L. Lessnick
Stephen L. Lessnick
Background Ewing sarcoma is an aggressive bone cancer in children and young adults that contains a pathognomonic chromosomal translocation: t(11;22)(q24;q12). The encoded protein, EWS/FLI, fuses the low-complexity amino-terminal portion of EWS to the carboxyl-terminus of FLI. The FLI portion contains an ETS DNA-binding domain and adjacent amino- and carboxyl-regions. Early studies using non-Ewing sarcoma cellular models provided conflicting information on the role of these adjacent regions in the oncogenic function of EWS/FLI. We therefore sought to define the specific contributions of each FLI region to EWS/FLI activity in an appropriate Ewing model, and in doing so, to better understand Ewing sarcoma development mediated by the fusion protein. Methods We used a “knock-down/rescue” system to replace endogenous EWS/FLI expression with mutant forms of the protein in Ewing sarcoma cells and tested these for oncogenic transformation using soft-agar colony forming assays. These data were complemented by DNA-binding assays using fluorescence anisotropy, genomic localization assays using CUT&RUN, transcriptional regulation studies using luciferase reporter assays and RNA-sequencing, as well as chromatin accessibility assays using ATAC-sequencing. Results We found that the DNA-binding domain and short flanking regions of FLI were required for oncogenic transformation, gene expression, genomic localization and chromatin accessibility when fused to the amino-terminal EWS-portion from EWS/FLI, but that the remaining regions of FLI were dispensable for these functions. Removal of a carboxyl-terminal alpha-helix from the short flanking regions of the DNA-binding domain of FLI created a hypomorphic EWS/FLI that retained normal DNA binding, genomic localization, and chromatin accessibility, but had significantly restricted transcriptional activity and a near total loss of oncogenic transformational capacity. Conclusions The DNA-binding domain and carboxyl-terminal short flanking region of FLI are the only portions of FLI required for EWS/FLI-mediated oncogenic transformation in a Ewing sarcoma cellular context. In addition to the well-defined DNA-binding function of FLI, this additional alpha-helix immediately downstream of the DNA-binding domain contributes a previously-undescribed function in gene regulation and oncogenic transformation. Understanding the function of this critical region could provide new therapeutic opportunities to target EWS/FLI in Ewing sarcoma.

9 May 2021 in medRxiv
Verified
Preprint
Open access
PDF file
MBMegann A. Boone
Megann A. Boone
CTCenny Taslim
Cenny Taslim
JCJesse C. Crow
Jesse C. Crow
JSJulia Selich-Anderson
Julia Selich-Anderson
MWMike Watson
Mike Watson
MWMark Winstanley
Mark Winstanley
Ewing sarcoma is an aggressive pediatric bone cancer defined by a chromosomal translocation fusing one of the FET family members to a member of the ETS transcription factor family. To date, there have been seven reported translocations, with the most recent translocation reported over a decade ago. We now report the first identification of a novel translocation occurring between the FUS gene and ETS family member ETV4 detected in a neonatal patient with Ewing sarcoma. Given its apparent rarity, we conducted an initial characterization of FUS/ETV4 function by performing genomic localization and transcriptional regulatory studies. We knocked down endogenous EWS/FLI in the A673 cell line, and expressed FUS/ETV4 in its stead, and performed CUT&Tag and RNA-sequencing analyses. We compared these data to similar “knock-down/rescue” analyses of other rare (non-EWS/FLI) Ewing sarcoma-associated translocation products. Through this comparative analysis in the same genetic background, we demonstrate significant similarities across these fusions, and in doing so, validate this novel FUS/ETV4 translocation as a bona fide Ewing sarcoma translocation. This study presents the first genomic comparisons of the rare Ewing sarcoma-associated translocation products, and reveals that the FET/ETS fusions share highly similar, but not identical, genomic localization and transcriptional regulation patterns. These data provide insights into the roles of both the FET and ETS sides of these fusions, and provide a generic strategy to provide further strength to the notion that FET/ETS fusions are key drivers of, and thus pathognomonic for, Ewing sarcoma. Significance: Identification and initial characterization of the novel Ewing sarcoma fusion, FUS/ETV4, expands the family of Ewing-fusions and extends the diagnostic possibilities for this aggressive tumor of adolescents and young adults.

8 August 2023
Verified
Other
Open access
PDF file
MBMegann A. Boone
Megann A. Boone
CTCenny Taslim
Cenny Taslim
JCJesse C. Crow
Jesse C. Crow
JSJulia Selich-Anderson
Julia Selich-Anderson
MWMike Watson
Mike Watson
MWMark Winstanley
Mark Winstanley
Supp Figure 7 contains results of a pathway analysis performed on FET/ETS-regulated genes in Ewing sarcoma cells.

8 August 2023
Verified
Other
Open access
PDF file
MBMegann A. Boone
Megann A. Boone
CTCenny Taslim
Cenny Taslim
JCJesse C. Crow
Jesse C. Crow
JSJulia Selich-Anderson
Julia Selich-Anderson
MWMike Watson
Mike Watson
MWMark Winstanley
Mark Winstanley
Supp Figure 6 demonstrates similar transcriptional regulatory patterns between FET/ETS proteins at Ewing sarcoma-specific genes.